Pathogenesis of Raynaud's phenomenon

Rheumatology

Volumn 44, Issue 5, 2005, Pages 587-596

  Herrick, A L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Endothelium; Nervous system; Pathophysiology; Platelet aggregation; Raynaud's phenomenon

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ARGININE; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUOXETINE; PROSTACYCLIN; PROSTANOID; SEROTONIN UPTAKE INHIBITOR;

BLOOD FLOW; BLOOD VESSEL TONE; BLOOD VESSEL WALL; BLOOD VISCOSITY; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE CLASSIFICATION; FIBRINOLYSIS; HUMAN; HYPERTRANSLUCENT LUNG; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN SECRETION; RAYNAUD PHENOMENON; RECEPTOR UPREGULATION; REVIEW; RHEUMATOLOGY; SENSORY NERVE; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; TISSUE INJURY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VIBRATION SYNDROME; HAND; HEMATOLOGIC DISEASE; MICROCIRCULATION; PERIPHERAL NEUROPATHY; VASCULARIZATION; VASOCONSTRICTION; VIBRATION;

HAND; HEMATOLOGIC DISEASES; HUMANS; MICROCIRCULATION; PERIPHERAL NERVOUS SYSTEM DISEASES; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VASOCONSTRICTION; VIBRATION;

EID: 21244444661     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh552     Document Type: Review

References (123)

1. Raynaud M. Local asphyxia and symmetrical gangrene of the extremities 1862. New researches on the nature and treatment of local asphyxia of the extremities 1874. Translated by Barlow. London: New Sydenham Society, 1888.
2. Lewis T. Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart 1929;15:7-101.
3. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001; 357:2042-8.
4. Al-Allaf A-W, Belch JJF. Raynaud's phenomenon. In: Hochberg MC, Silman AJ, Smolen JS et al., eds. Rheumatology, 3rd edn. Elsevier, Edinburgh, 2003;1507-1512.
5. Kaheleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995;38:1-4.
6. Bukhari M, Herrick AL, Moore T, Manning J, Jayson MIV. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996;35: 1127-31.
7. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin Arthritis Rheum 1975;4:351-68.
8. Rodnan GP, Myerowitz RL, Justh GO. Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine 1980;59: 393-408.
9. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
10. Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999;31:195-214.
11. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91.
12. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmume Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 1999;42:930-41.
13. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
14. Takeuchi T, Futatsuka M, Imanishi H, Yamada S. Pathological changes observed in the finger biopsy of patients with vibration-induced white finger. Scand J Work Environ Health 1986;12:280-3.
15. Littleford RC, Khan F, Hindley MO, Ho M, Belch JJF. Microvascular abnormalities in patients with vibration white finger. Q J Med 1997;90:525-9.
16. Herrick AL, Illingworth K, Blann A, Hay CRM, Hollis S, Jayson MIV. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
17. Celermajer DS, Sorenson KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
18. Anderson ME, Hollis S, Moore T, Jayson MIV, Herrick AL. Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996;35:1281-8.
19. Anderson ME, Campbell F, Hollis S, Moore T, Jayson MIV, Herrick AL. Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenomenon and systemic sclerosis. Clin Exp Rheumatol 1999;17:49-54.
20. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990;8:561-5.
21. Lekakis J, Mavrikakis M, Papamicheal C et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998;136:905-12.
22. Freedman RF, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8.
23. Khan F, Belch JJF. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: Effects of oral L-arginine supplementation. J Rheumatol 1999;26:2389-94.
24. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-33.
25. Anderson ME, Moore TL, Hollis S, Clark S, Jayson MI, Herrick AL. Endothelial-dependent vasodilation is impaired in patients with systemic sclerosis, as assessed by low dose iontophoresis. Clin Exp Rheumatol 2003;21:403.
26. Anderson ME, Moore TL, Lunt M, Herrick AL. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging - a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatol 2004;43:986-91.
27. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud's disease. Lancet 1993;342:1451-4.
28. Smith PJW, Ferro CJ, McQueen DS, Webb DJ. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. Br J Clin Pharmacol 1999;47:507-13.
29. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJF. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997;40:352-7.
30. Teh LS, Manning J, Moore T, Tully MP, O'Reilly D, Jayson MIV. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995;34:636-41.
31. Khan F, Greig IR, Newton DJ, Butler AR, Belch JJF. Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet 1997;350: 410-1.
32. Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud's syndrome: A randomised trial. Lancet 1999;354:1670-5.
33. Anderson ME, Moore TL, Hollis S, Jayson MIV, King TA, Herrick AL. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatol 2002;41:324-8.
34. Yamamoto T, Katayama I, Nichioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998;25:314-7.
35. Cotton SA, Herrick AL, Jayson MIV, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999;189:273-8.
36. Rajagopalan S, Pfenninger D, Kehrer C et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon. Implications for vascular dysfunction and progression of disease. Arthritis Rheum 2003;48:1992-2000.
37. 2 synthesis: Relevance to cold-induced pathology. Microcir, Endo, Lymp 1988;4:3-20.
38. Belch JJF, McLaren M, Anderson J et al. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukotrienes Med 1985;17:1-9.
39. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999;221:312-5.
40. Smythe AE, Bell AL, Bruce IN, McGrann S, Allen JA. Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 2000;59: 870-4.
41. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-76.
42. Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993;101:73-8.
43. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358:1119-23.
44. Rubin U, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
45. Korn JH, Mayes M, Matucci-Cerinic M et al. Digital ulcers in systemic sclerosis - prevention by treatment with bosentan, and oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
46. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990;336:1144-7.
47. Leppert J, Ringqvist A, Karlberb BE, Ringquist I. Whole-body cooling increases plasma endothelin-1 levels in women with primary Raynaud's phenomenon. Clin Physiol 1998;18:420-25.
48. Palmer KT, Mason H. Serum endothelin concentrations in workers exposed to vibration. Occup Environ Med 1996;53:118-24.
49. Kawaguchi Y, Takagi K, Hara M et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004; 50:216-26.
50. Mancini GB, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996;94:258-65.
51. Dziadzio M, Denton CP, Smith R et al. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized. parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-55.
52. Furspan PB, Chatter S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004;50:1578-85.
53. Charkoudian N. Skin blood flow in adult human thermoregulation: How it works, when it does not, and why. Mayo Clin Proc 2003; 78:603-12.
54. Klimiuk PS, Taylor L, Baker RD, Jayson MIV. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 1988;47:542-5.
55. Dessein PH, Joffe BJ, Metz RM, Millar DL, Lawson M, Stanwix AE. Autonomic dysfunction in systemic sclerosis: Sympathetic overactivity and instability. Am J Med 1992;93:143-50.
56. Schady W, Sheard A, Hassell A, Holt L, Jayson MIV, Klimiuk P. Peripheral nerve dysfunction in scleroderma. Q J Med 1991;84:661-75.
57. Herrick AL. Nervous system. In: Clements PJ, Furst DE, eds. Systemic sclerosis, 2nd edn. Philadelphia: Williams & Wilkins, 2004;309-17.
58. Noel B. Pathophysiology and classification of the vibration white finger. Int Arch Occup Environ Health 2000;73:150-5.
59. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336:1530-3.
60. Goldsmith PC, Molina FA, Bunker CB et al. Cutaneous nerve fibre depletion in vibration white finger. J R Soc Med 1994;87: 377-81.
61. Terengi G, Bunker CB, Liu YF et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. J Pathol 1991;164:245-52.
62. Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993;342:80-3.
63. Ekenvall L, Lindblad LE. Is vibration white finger a primary sympathetic nerve injury? Br J Ind Med 1986;43:702-6.
64. 2 receptor hypersensitivity in Raynaud's phenomenon. J Vasc Med Biol 1990;2:100-6.
65. 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993;36:685-90.
66. Freedman RR, Baer RP, Mayes MD. Blockade of vasospastic attacks by alpha2-adrenergic but not alpha1-adrenergic antagonists in idiopathic Raynaud's disease. Circulation 1995;92:1448-51.
67. Cooke JP, Creager SJ, Scales KM et al. Role of digital artery adrenoceptors in Raynaud's disease. Vascular Med 1997;2:1-7.
68. Freedman RF, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8.
69. 2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43:1886-90.
70. Guimaraes S, Moura D. Vascular adrenoceptors: An update. Pharmacol Rev 2001;53:319-56.
71. Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest 1988;18:309-13.
72. Ekenvall L, Lindblad LE, Norbeck O. Etzell B-M. α-Adrenoceptors and cold-induced vasoconstriction in human finger skin. Am J Physiol 1988;255:H1000-3.
73. 2-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000;278: H1075-83.
74. 2-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol 2001;60:1195-200.
75. Flavahan NA, Cooke JP, Shepherd JT, Vanhoutte PM. Human postjunctional alpha-1 and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1987;241:361-5.
76. Edwards CM, Marshall JM, Pugh M. Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease. Clin Sci 1998;95:249-60.
77. Edwards CM, Marshall JM, Pugh M. Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: The role of endothelin. Clin Sci 1999;96:577-88.
78. Ishida T, Takahashi M, Corson MA, Berk BC. Fluid shear stress-mediated signal transduction: How do endothelial cells transduce mechanical force into biological responses? Ann NY Acad Sci 1997;811:12-23.
79. Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell antibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996;97:111-9.
80. Kahaleh MB, Osborn I, LeRoy EC. Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610-3.
81. Kallenberg CGM, Vellenga E, Wouda AA, The TH. Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol 1982;9:878-84.
82. Seibold JR, Harris JN. Plasma β-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J Rheumatol 1985;12:99-103.
83. Lau CS, McLaren M, Saniabadi A, Belch JJF. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993;22:97-101.
84. Silveri F, De Angelis R, Poggi A et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001;30:290-6.
85. Kent PJ, Williams GA, Kester RC. Platelet activation during hand vibration. Br J Surg 1994;81:815-8.
86. Reilly IA, Roy L, Fitzgerald GA. Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. Br Med J 1986;292:1037-9.
87. Young V, Ho M, Vosper H, Belch JJF, Palmer CNA. Elevated expression of the genes encoding TNF-α and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology 2002;41:869-75.
88. Klimiuk PS, Grennan A, Weinkove C, Jayson MIV. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989;48:586-9.
89. Lau CS, McLaren M, Mackay I, Belch JJF. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis 1993;52:443-8.
90. Ames PR, Lupoli S, Alves J et al. The coagulation/fibrinolytic balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br J Rheumatol 1997;36:1045-50.
91. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992;11:375-82.
92. Lau CS, O'Dowd A, Belch JJF. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration white finger. Ann Rheum Dis 1992;51:249-52.
93. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJF. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 1992;31: 375-80.
94. Rustin MHA, Kovacs IB, Sowemimo-Coker SO, Maddison PJ, Kirby JDT. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease. Br J Dermatol 1985;113:265-72.
95. Solans R, Motta C, Sola R et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis. Arthritis Rheum 2000;43:894-900.
96. Goyle KB, Dormandy JA. Abnormal blood viscosity in Raynaud's phenomenon. Lancet 1976;i:1317-8.
97. Picart C, Carpentier PH, Brasseur S, Galliard H, Piau JM. Systemic sclerosis: Blood rheometry and laser Doppler imaging of digital cutaneous microcirculation during local cold exposure. Clin Hemorheol Microcirc 1998;18:47-58.
98. Okada A, Inaba R, Furono T, Nohara S, Ariizumi M. Usefulness of blood parameters, especially viscosity, for the diagnosis and elucidation of pathogenic mechanisms of the hand-arm vibration syndrome. Scand J Work Environ Health 1987;13:358-62.
99. Greenstein D, Kester RC. The hemorheologic effects of hand-transmitted vibration. Angiology 1997;48:813-9.
100. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
101. Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001;19:4-8.
102. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MIV. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994;21:1477-83.
103. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
104. Simonini G, Matucci Cerinic M, Generini S et al. Oxidative stress in systemic sclerosis. Mol Cell Biochem 1999;196:85-91.
105. Herrick AL, Illingworth KJ, Hollis S, Gomez-Zumaquero JM, Tinahones FJ. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatol 2001;40:401-5.
106. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking: A significant risk factor for digital vascular diseases in patients with systemic sclerosis. Arthritis Rheum 2002;46:3312-6.
107. Cherniack M, Clive J, Seidner A. Vibration exposure, smoking, and vascular dysfunction. Occup Environ Med 2000;57:341-7.
108. Palesch YY, Valter I, Carpentier PH, Maricq HR. Association between cigarette and alcohol consumption and Raynaud's phenomenon. J Clin Epidemiol 1999;52:321-8.
109. Lafferty K, de Trafford JC, Potter C, Roberts VC, Cotton LT. Reflex vascular responses in the finger to contralateral thermal stimuli during the normal menstrual cycle: A hormonal basis to Raynaud's phenomenon? Clin Sci 1985;68:639-45.
110. Freedman RR, Mayes MD. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996;39:1189-91.
111. Susol E, MacGregor AJ, Barrett JH et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43:1641-6.
112. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
113. Zhou X, Tan FK, Wang N et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003;48:2585-92.
114. Newman JH, Wheeler L, Lane KB et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24.
115. Trembath RC, Thompson JR, Machado RD et al. Clinical and molecular genetics of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-34.
116. Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology 2002;41:965-71.
117. Weber KT, Brilla CG, Janicki JS. Cardioreparation with lisinopril in the management of hypertension and heart failure. Cardiology 1991;79(Suppl.):62-73.
118. Coleiro B, Marshall SE, Denton CP et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038-43.
119. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
120. Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software, 2002.
121. Fishman AP. Pulmonary hypertension - beyond vasodilator therapy. N Engl J Med 1998;338:321-2.
122. Denton CP, Bunce TD, Dorado MB et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 1999;38:309-15.
123. Herrick AL, Hollis S, Schofield D et al. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000;18:349-56.